> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Exploring CBD Regulatory Paths
- URL: https://www.fdaweb.com/fda-exploring-cbd-regulatory-paths/
- Published: 2020-02-26T12:00:00.000Z
- Updated: 2026-09-14T16:04:32.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146187

FDA commissioner **Stephen Hahn** says the agency is evaluating potential regulatory pathways outside of the existing drug pathway that would allow various types of CBD products to be lawfully marketed. In a 2/26 [presentation](https://www.fda.gov/news-events/speeches-fda-officials/remarks-stephen-hahn-nasda-winter-policy-conference-02262020?ref=fdaweb.com) to the National Association of State Departments of Agriculture, Hahn said the agency wants to “empower the American consumer with accurate information about CBD and the role that FDA plays.”

He said that as the evaluation of potential regulatory pathways continues, FDA will remain focused on the many unanswered questions concerning the safety of CBD in unapproved medical products, consumer products, and foods. “For instance,” he said, “there’s still much we don’t know about the effects of sustained, long-term exposure to these products. I can assure you that FDA will move forward carefully and deliberately as we determine the appropriate path to take.”

He said the agency’s approach to this and all other questions will involve reliance on the best available science.